Annals of Surgical Oncology最新文献

{"title":"ASO Author Reflections: The Two Faces of Late Mortality in Early-Onset Solid Cancer Survivors After Surgery.","authors":"Jian Li, Xiaohong Kuang","doi":"10.1245/s10434-026-20570-y","DOIUrl":"10.1245/s10434-026-20570-y","url":null,"abstract":"","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"10767"},"PeriodicalIF":3.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148954692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant Immunotherapy in Localized dMMR/MSI-H Colon Cancer: A Systematic Review of Pathological Response and Surgical Outcomes.","authors":"Rathin Gosavi, Baxter Smith, Hanumant Chouhan, Thang Chien Nguyen, William Teoh, Paul McMurrick, Vignesh Narasimhan","doi":"10.1245/s10434-026-20430-9","DOIUrl":"10.1245/s10434-026-20430-9","url":null,"abstract":"<p><strong>Background: </strong>Neoadjuvant immune checkpoint inhibition is increasingly being investigated in localized mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) colon cancer, but evidence remains immature and often combined with broader cohorts.</p><p><strong>Methods: </strong>We reviewed prospective interventional studies of neoadjuvant immune checkpoint inhibition in adults with localized, non-metastatic dMMR/MSI-H colon cancer. The Ovid MEDLINE, Embase, Web of Science, Cochrane Library, and ClinicalTrials.gov databases and reference lists were searched to 12 June 2026. Studies were eligible when colon-specific pathological response outcomes were reported or extractable. Primary outcomes were pathological complete response (pCR) and major pathological response (MPR). Secondary outcomes included surgical feasibility, R0 resection, delay, morbidity, adverse events, recurrence, and survival.</p><p><strong>Results: </strong>Six studies were included: NICHE, NICHE-2, NICHE-3, RESET-C, IMHOTEP, and IBI310/sintilimab. pCR ranged from 44 to 78.4% and MPR from 57 to 95%, varying by regimen, denominator, and definition. NICHE-based dual-checkpoint studies reported pCR rates of 60-68% and MPR rates of 92-95%. Pembrolizumab-based studies reported pCR rates of 44-62.7%. The only randomized comparative study favored CTLA-4 plus programmed cell death protein-1 blockade over programmed cell death protein-1 blockade alone. Most patients proceeded to colectomy, with high R0 resection rates where reported. Severe treatment-related or immune-related adverse events occurred, including rare grade 5 events. Follow-up ranged from 8.1 to 26 months; recurrence was uncommon and survival outcomes immature.</p><p><strong>Conclusions: </strong>Neoadjuvant immune checkpoint inhibition demonstrates substantial pathological activity and apparent surgical feasibility in selected localized dMMR/MSI-H colon cancer. Longer follow-up and comparative trials are needed to define regimen, timing, patient selection, and durable oncological benefit.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"10641-10650"},"PeriodicalIF":3.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13675335/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148787343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overall and Cause-Specific Late Mortality in Long-Term Survivors of Early Onset Solid Cancer After Surgery: A Population-Based Retrospective Cohort Study.","authors":"Jian Li, Xiaohong Kuang","doi":"10.1245/s10434-026-20389-7","DOIUrl":"10.1245/s10434-026-20389-7","url":null,"abstract":"<p><strong>Background: </strong>Late mortality of early onset solid cancer survivors remains poorly characterized. We quantified the late mortality among 5-year survivors of early onset solid cancers following surgery.</p><p><strong>Patients and methods: </strong>This retrospective cohort study analyzed data from the Surveillance, Epidemiology, and End Results (SEER) database, including 5-year survivors of solid cancer at age 20-49 years following surgery during 1975-2017. We estimated the cumulative mortality probabilities, standardized mortality ratios (SMRs), and absolute excess risks (AERs) for all-cause and cause-specific mortality compared with the general population.</p><p><strong>Results: </strong>A total of 294,994 survivors (median age 42 years, IQR 35-46 years) were included, with median follow-up of 17.8 years (IQR 10.7-26.8 years). At 40 years post-diagnosis, cumulative all-cause mortality reached 50.0% (95% CI 49.6-50.4%). While recurrence or progression dominated mortality initially, non-cancer health-related causes ultimately became the leading contributor to death. Overall, survivors exhibited significantly elevated all-cause mortality compared with the general population (SMR 1.77, 95% CI 1.76-1.79). On the basis of non-cancer health-related mortality, two distinct survivor groups emerged: 13 cancers with increased mortality (SMR 1.41, 95% CI 1.38-1.44) and 6 cancers with decreased mortality (SMR 0.78, 95% CI 0.77-0.80) relative to the general population.</p><p><strong>Conclusions: </strong>Long-term early onset solid cancer survivors after surgery face substantial late mortality burden, with non-cancer health-related causes ultimately surpassing recurrence or progression as the leading cause of death. On the basis of non-cancer health-related mortality, increased-risk and decreased-risk cancer types can be distinguished.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"10750-10759"},"PeriodicalIF":3.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148757832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nationwide Implementation of Neoadjuvant Nivolumab-Based Chemo-Immunotherapy for Resectable NSCLC: Surgical Outcomes from a Prospective Multicenter Study.","authors":"Jiri Vachtenheim, Fernando Casas-Mendez, Rene Novysedlak, Janis Tavandzis, Linda Capkova, Jaromir Vajter, Marek Szkorupa, Juraj Kultan, Alice Taskova, Martina Koziar Vasakova, Martin Skala, Martin Svaton, Vilem Maly, David Sulc, Ivo Hanke, Michal Hrnciarik, Ladislav Mitas, Monika Bratova, Lubomir Tulinsky, Radoslava Cernekova, Zuzana Ozaniak Strizova, Matyas Kuhn, Boris Sepesi, Jitka Palich Fucikova, Robert Lischke","doi":"10.1245/s10434-026-20310-2","DOIUrl":"10.1245/s10434-026-20310-2","url":null,"abstract":"<p><strong>Background: </strong>Neoadjuvant chemo-immunotherapy has transformed the treatment landscape for resectable non-small-cell lung cancer (NSCLC). However, real-world surgical data from nationwide European cohorts remain limited. This study evaluated surgical outcomes and practice patterns during the first year of nationwide implementation of neoadjuvant chemo-immunotherapy with nivolumab in the Czech Republic.</p><p><strong>Methods: </strong>This prospective, multicenter, observational cohort study included all consecutive patients with resectable programmed cell death ligand-1(PD-L1) ≥ 1% NSCLC treated according to the CheckMate 816 protocol (platinum-based chemotherapy plus nivolumab) at all eight accredited thoracic oncology centers in the Czech Republic between August 2023 and August 2024. Surgical and pathological outcomes were assessed.</p><p><strong>Results: </strong>Sixty-four patients initiated neoadjuvant therapy and 56 (87.5%) underwent resection. Minimally invasive surgery was attempted in 46.4% of cases, with an 11.5% conversion rate. Clavien-Dindo grade ≥ III complications occurred in 14.3%, with grade IIIb representing the highest severity. 30-day mortality was 0%. Although 90-day mortality was 5.4%, none of the deaths were directly attributable to surgery. R0 resection was achieved in 98.2%. In the intention-to-treat population, pathological complete response and major pathological response rates were 40.6% and 48.4%, respectively. Pathological complete response was significantly higher in squamous than in non-squamous NSCLC (66.7% vs. 27.6%; p = 0.003).</p><p><strong>Conclusions: </strong>In this first nationwide cohort from a European country, early adoption of neoadjuvant chemo-immunotherapy with nivolumab in patients with resectable PD-L1 ≥ 1% NSCLC was associated with acceptable perioperative outcomes, high R0 resection rates, and substantial pathological response. These results demonstrate the successful adoption of a novel NSCLC treatment modality across a nationwide healthcare system.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"10312-10325"},"PeriodicalIF":3.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13675273/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148618206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Systematic Review and Meta-Analysis of Surgical Feasibility and Outcomes Following Neoadjuvant Immune Checkpoint Inhibition in Resectable Stage III and IV Melanoma.","authors":"T Read, G Nair, G Velli, M David, G Bayley, Wen Xu, A Barbour, B M Smithers, V Atkinson","doi":"10.1245/s10434-026-20067-8","DOIUrl":"10.1245/s10434-026-20067-8","url":null,"abstract":"<p><strong>Background: </strong>Neoadjuvant immune checkpoint inhibition (ICI) has demonstrated high pathological response rates in resectable stage III melanoma and is increasingly used for selected patients with low-volume stage IV disease. However, the surgical and perioperative implications remain incompletely defined. A systematic review and meta-analysis were performed to evaluate oncologic, surgical, and immune-related outcomes following neoadjuvant ICI and curative-intent surgery.</p><p><strong>Materials and methods: </strong>MEDLINE, EMBASE, and the Cochrane Library, were systemically searched for both prospective and retrospective studies including adults with resectable stage III or oligometastatic stage IV melanoma treated with neoadjuvant ICI followed by planned surgery. Outcomes included pathological response, recurrence, failure or delay to surgery, perioperative complications, and treatment-related adverse events. Pooled estimates were calculated using random-effects meta-analyses.</p><p><strong>Results: </strong>A total of 20 studies comprising 1384 patients were included. The pooled proportions of pathological complete response were 0.33 (CI 0.26-0.40), major pathological response 0.46 (CI 0.38-0.54), and overall pathological response 0.59 (CI 0.51-0.67). Pathological nonresponse occurred in 0.30 (CI 0.25-0.36). Failure or delay to surgery occurred in 0.09 (CI 0.07-0.12), with disease progression during neoadjuvant therapy reported in 0.06 (CI 0.04-0.10). Major perioperative complications (Clavien-Dindo ≥ III) occurred in 0.08 (CI 0.05-0.13), while major treatment-related toxicities (CTCAE grade ≥ III) occurred in 0.25 (CI 0.18-0.34). Comparative analyses demonstrated similar perioperative complication rates between neoadjuvant and adjuvant approaches, with lower recurrence risk favoring neoadjuvant therapy (p < 0.01).</p><p><strong>Conclusions: </strong>Neoadjuvant ICI produces substantial pathological responses while preserving surgical feasibility in resectable stage III and selected stage IV melanoma. Operative morbidity appears acceptable; however, systemic toxicity is common, and perioperative reporting remains heterogeneous.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"10772-10784"},"PeriodicalIF":3.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13675365/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148418294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ASO Author Reflections: Beyond Tumor Biology: Integrating Host Physiological Reserve into Perioperative Esophageal Cancer Care.","authors":"Yizhou Huang, Maohui Chen, Zhenyuan Yang, Wei Li, Chun Chen, Bin Zheng","doi":"10.1245/s10434-026-20297-w","DOIUrl":"10.1245/s10434-026-20297-w","url":null,"abstract":"","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"10395-10396"},"PeriodicalIF":3.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148496954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlations Between the Histologic Growth Patterns of Peritoneal and Liver Metastases From Colorectal Cancer.","authors":"Noémie Zenaty, Radu Bachmann, Charif Khaled, Pieter Demetter, Francesco Sclafani, Pamela Baldin, Ana Veron Sanchez, Michel Moreau, Vincent Donckier, Gabriel Liberale","doi":"10.1245/s10434-026-20005-8","DOIUrl":"10.1245/s10434-026-20005-8","url":null,"abstract":"<p><strong>Background: </strong>Histologic growth patterns (HGPs) of both peritoneal metastasis (PM) and liver metastasis (LM) have emerged as prognostic factors for patients undergoing curative surgery for metastatic colorectal cancer (CRC). The main objectives of the study were, first, to evaluate the correlation between PMHGP and LMHGP of CRC patients who underwent curative-intent cytoreductive surgery (CRS) and LM resection and, second, to assess the prognostic impact of HGP type.</p><p><strong>Methods: </strong>This retrospective bicentric study included patients treated with both CRS and LM resection for metastatic CRC. Histologic growth patterns were classified as pushing (P-HGP) and infiltrating (I-HGP) for PM, and as desmoplastic HGP (D-HGP) and non-desmoplastic (ND-HGP) for LM. Correlation between PMHGP and LMHGP was assessed using the chi-square test. Overall survival (OS) and disease-free survival (DFS) were evaluated using Kaplan-Meier and Cox regression.</p><p><strong>Results: </strong>The study included 44 patients. Of the 44 patients, 9 (20.5%) had P-HGP + D-HGP, 23 (52.3%) had I-HGP + ND-HGP, 5 (11.4%) had P-HGP + ND-HGP, and 7 (15.9%) had I-HGP + D-HGP. Significant correlation was observed between PMHGP and LMHGP (p = 0.0085; Φ = 0.3965). The patients with I-HGP + ND-HGP had shorter OS and DFS than those with other combinations: 34 versus 64 months (HR, 2.067; p = 0.0672) for OS, and 14 versus 25 months (hazard ratio [HR], 1.775; p = 0.1071) for DFS.</p><p><strong>Conclusions: </strong>This study highlighted a significant correlation between PMHGP and LMHGP in metastatic CRC. However, survival trends were nonsignificant.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"10415-10424"},"PeriodicalIF":3.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13675321/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148343805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Surgical Therapy in Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma and Development of a Survival Nomogram.","authors":"Ke Wang, Deyu Yang, Zhichao Li, Xinrong Chen, Tengjiao Lin, Linzhu Zhai","doi":"10.1245/s10434-026-20313-z","DOIUrl":"10.1245/s10434-026-20313-z","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to investigate the clinical characteristics, prognostic factors, and treatment outcomes of patients with pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma.</p><p><strong>Methods: </strong>The Surveillance, Epidemiology, and End Results (SEER) database was queried for patients with a diagnosis of pulmonary MALT lymphoma between 2000 and 2020.</p><p><strong>Results: </strong>Between 2000 and 2020, a total of 1721 patients had a diagnosis of pulmonary MALT lymphoma. Among the stages I and II patients, those treated with surgery outperformed those treated with radiotherapy in survival trends, but attention should be paid to potential selection bias. Among the patients who received combination therapy, those who received surgery combined with chemotherapy had longer overall survival (OS). Multifactorial Cox regression analysis identified sex, age, Ann Arbor stage, and surgery as prognostic factors for OS. A nomogram was established for pulmonary MALT lymphoma to predict OS, with a concordance index (C-index) of 0.718 and area under curve values of 0.7235, 0.7328, and 0.7917 for the 3-, 5-, and 10-year survival rates of the nomogram, respectively, indicating that the predicted probability of the calibration curve agreed well with the actual value.</p><p><strong>Conclusions: </strong>Pulmonary MALT lymphoma is a type of indolent lymphoma with a good prognosis, and surgery may be associated with improved patient survival outcomes, but this association needs to be further validated in prospective studies. This study established a nomogram that has good applicability for predicting long-term OS for patients.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"10366-10374"},"PeriodicalIF":3.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13675303/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148787527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Outcomes of Neoadjuvant Chemoimmunotherapy Versus Chemoradiation Combined with Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis.","authors":"Xin Xiao, Pinhao Fang, Chengyi Mao, Jianfeng Zhou, Yushang Yang, Siyuan Luan, Xiaokun Li, Haowen Zhang, Yong Yuan","doi":"10.1245/s10434-026-20415-8","DOIUrl":"10.1245/s10434-026-20415-8","url":null,"abstract":"<p><strong>Background: </strong>Neoadjuvant chemoimmunotherapy (NCIT) has emerged as a promising strategy for patients with esophageal squamous cell carcinoma (ESCC). However, whether neoadjuvant chemoradiation-immunotherapy (NCRI) can further improve therapeutic efficacy remains uncertain.</p><p><strong>Methods: </strong>This study prospectively enrolled and retrospectively analyzed 557 consecutive patients with locally advanced ESCC who underwent neoadjuvant therapy between December 2019 and January 2025. The participants were stratified into two treatment cohorts: those receiving NCIT and those undergoing NCRI. To mitigate potential selection bias and ensure balanced baseline characteristics between groups, a 1:1 propensity score-matching (PSM) protocol was implemented incorporating multiple clinically relevant covariates to assess short-term pathologic outcomes and long-term survival.</p><p><strong>Results: </strong>After PSM, these baseline characteristics were well balanced, with 124 patients in each group. The NCRI group demonstrated superior pathologic outcomes, with a significantly higher pathologic complete response (pCR) rate (41.1% vs 19.4%; P < 0.001) and a lower tumor regression score (TRS; P < 0.001), but also a higher incidence of postoperative pulmonary complications (37.1% vs 16.9%; P < 0.001). Despite these differences, no significant variation in overall survival (OS; P = 0.837) or disease-free survival (DFS; P = 0.429) was observed between the two groups during the follow-up period.</p><p><strong>Conclusions: </strong>The addition of radiotherapy to NCIT significantly improved pCR rates compared with NCIT alone, but was associated with a higher incidence of postoperative pulmonary complications. However, this pathologic benefit did not translate into superior long-term survival outcomes in either OS or DFS.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"10356-10365"},"PeriodicalIF":3.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148787588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ASO Author Reflections: Proximal Gastrectomy After Neoadjuvant Therapy: Function-Preserving Surgery for Gastroesophageal Junction Cancer.","authors":"Ze-Lin Wen, Hu Ren, Diliyaer Adili, He Fei, Peng-Hui Niu, Ze-Feng Li, Hong-Xu Nie, Dong-Bing Zhao","doi":"10.1245/s10434-026-20571-x","DOIUrl":"10.1245/s10434-026-20571-x","url":null,"abstract":"","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"10736-10737"},"PeriodicalIF":3.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148987906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}